Rwanda and European Union: Signature of four contracts for the development of the pharmaceutical sector
A strategic partnership for the Rwandan pharmaceutical industry
Rwanda, with the support of the European Union (EU), is pursuing its ambition to become a pharmaceutical hub in Africa. On September 17, 2024, the two parties signed four contracts worth $44 million, aimed at strengthening the development of the local pharmaceutical industry. According to the Rwandan Ministry of Foreign Affairs, these agreements will focus on skills improvement, research and development (R&D), clinical trials, as well as strengthening supply chains and the regulatory framework.
A commitment from the European Union to support Africa
These contracts are part of a commitment made in December 2023 by Ursula Von der Leyen, President of the European Commission, during her meeting with President Paul Kagame. Rwanda, which has already undertaken several initiatives in the pharmaceutical sector, is thus benefiting from the EU’s support to achieve its objectives of local production of vaccines and medicines. This effort is part of Africa’s desire to reduce its dependence on imports, particularly after the Covid-19 crisis, when the continent struggled to obtain vaccine doses.
Objective: An African pharmaceutical hub
In 2021, Rwanda already welcomed its first mobile vaccine production units, delivered by BioNTech. These facilities are expected to eventually produce between 50 and 100 million doses per year. This initiative is also in line with the African Union (AU) ambition to increase local vaccine production in Africa from 1% to 60% by 2040. Rwanda, thanks to its dynamic economy, is positioning itself as a key player in this transformation, notably by hosting the headquarters of the new African Medicines Agency (AMA).
Conclusion
Through this enhanced collaboration with the European Union, Rwanda is taking another step towards its goal of becoming a pharmaceutical leader in Africa. This strategic partnership, focused on developing local infrastructure and skills, offers the country a unique opportunity to play a central role in the production of medicines and vaccines for the continent, while reducing its dependence on imports.
